NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Introduction For opioid-dependent patients in the US and elsewhere, detoxification and counseling-only aftercare are treatment mainstays. Long-term abstinence is rarely achieved; many patients relapse and overdose after detoxification. Methadone, buprenorphine-naloxone (BUP-NX) and extended-release naltrexone (XR-NTX) can prevent opioid relapse but are underutilized. This study is intended to develop an evidence-base to help patients and providers make informed choices and to foster wider adoption of relapse-prevention pharmacotherapies. Methods The National Institute on Drug Abuse's Clinical Trials Network (CTN) study CTN-0051, X:BOT, is a comparative effectiveness study of treatment for 24 weeks with XR-NTX, an opioid antagonist, versus BUP-NX, a high affinity partial opioid agonist, for opioid dependent patients initiating treatment at 8 short-term residential (detoxification) units and continuing care as outpatients. Up to 600 participants are randomized (1:1) to XR-NTX or BUP-NX. Results The primary outcome is time to opioid relapse (i.e., loss of persistent abstinence) across the 24-week treatment phase. Differences between arms in the distribution of time-to-relapse will be compared (construction of the asymptotic 95% CI for the hazard ratio of the difference between arms). Secondary outcomes include proportions retained in treatment, rates of opioid abstinence, adverse events, cigarette, alcohol, and other drug use, and HIV risk behaviors; opioid cravings, quality of life, cognitive function, genetic moderators, and cost effectiveness. Conclusions XR-NTX and BUP-NX differ considerably in their characteristics and clinical management; no studies to date have compared XR-NTX with buprenorphine maintenance. Study design choices and compromises inherent to a comparative effectiveness trial of distinct treatment regimens are reviewed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110
Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002209.pub2 · Cited by 1,654
Measuring nicotine dependence: A review of the Fagerstrom Tolerance Questionnaire
Fagerstrom, K. O., & Schneider, N. G. (1989) · Journal of Behavioral Medicine · doi:10.1007/bf00846549 · Cited by 1,598
A "SMART" Design for Building Individualized Treatment Sequences
Lei, H., Nahum-Shani, I., Lynch, K., Oslin, D., & Murphy, S. A. (2012) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032511-143152 · Cited by 557
Krupitsky, E., Nunes, E. V., Ling, W., Illeperuma, A., Gastfriend, D. R., & Silverman, B. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60358-9 · Cited by 555
Self-citationBuprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Kimber, J., Breen, C., & Davoli, M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub3 · Cited by 501
Extended-release naltrexone to prevent opioid relapse in criminal justice offenders
Lee, J. D., Friedmann, P. D., Kinlock, T. W., Nunes, E. V., Boney, T. Y., Hoskinson, R. A., Wilson, D., McDonald, R., Rotrosen, J., Gourevitch, M. N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505409 · Cited by 315
Self-citationPharmacotherapy in the Treatment of Addiction: Methadone
Kreek, M. J., Borg, L., Ducat, E., & Ray, B. (2010) · Journal of Addictive Diseases · doi:10.1080/10550881003684798 · Cited by 108
Cited by
Lee, J. D., Nunes, E. V., Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., Farkas, S., Fishman, M., Gauthier, P., Hodgkins, C. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32812-x · Cited by 700
Self-citationMorgan, J. R., Schackman, B. R., Leff, J. A., Linas, B. P., & Walley, A. Y. (2018) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2017.07.001 · Cited by 332
Hadland, S. E., Wharam, J. F., Schuster, M. A., Zhang, F., Samet, J. H., & Larochelle, M. R. (2017) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2017.0745 · Cited by 294
(2018) · PubMed · Cited by 14
Gold, M. S., Blum, K., Bowirrat, A., Pinhasov, A., Bagchi, D., A. Dennen, C., K. Thanos, P., Hanna, C., Lewandrowski, K.-U., Sharafshah, A., et al. (2024) · INNOSC Theranostics and Pharmacological Sciences · doi:10.36922/itps.1918 · Cited by 9
Metadata
- Authors
- Lee, J. D., Nunes, E. V., MPA, P. N., Bailey, G. L., Brigham, G. S., Cohen, A. J., Fishman, M., Ling, W., Lindblad, R., Shmueli-Blumberg, D., Stablein, D., May, J., Salazar, D., Liu, D., & Rotrosen, J.
- Venue
- Contemporary Clinical Trials
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 50
- Pages
- 253-264
- ISSN
- 1551-7144 (ISSN-L)
- OpenAlex
- W2517652980
- Cited by
- 63
- References
- 8
- FWCI
- 4.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale. https://app.cochat.ai/papers/10.1016/j.cct.2016.08.004
- The paper
- Lee, J. D., Nunes, E. V., MPA, P. N., Bailey, G. L., Brigham, G. S., Cohen, A. J., Fishman, M., Ling, W., Lindblad, R., Shmueli-Blumberg, D., Stablein, D., May, J., Salazar, D., Liu, D., & Rotrosen, J. (2016). NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale. Contemporary Clinical Trials. https://doi.org/10.1016/j.cct.2016.08.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.